Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.7 USD | +10.33% | -0.21% | -51.14% |
May. 10 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
May. 10 | Sector Update: Health Care | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 532.7 | 1,285 | 983.2 | 412.5 | 596.7 | 294.4 | - | - |
Enterprise Value (EV) 1 | 316.9 | 1,104 | 983.2 | 412.5 | 366.9 | 230.4 | 294.4 | 294.4 |
P/E ratio | -3.44 x | -9.26 x | -4.76 x | -3.44 x | -64.1 x | -1.57 x | -2.58 x | -2.29 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 8.3 x | 12.3 x | 12.7 x | 2.71 x | 10.2 x | 4.48 x | 2.71 x | 2.62 x |
EV / Revenue | 4.94 x | 10.5 x | 12.7 x | 2.71 x | 6.25 x | 3.5 x | 2.71 x | 2.62 x |
EV / EBITDA | -1.91 x | -9.25 x | -5.13 x | -3.77 x | -2.31 x | -1.18 x | -2.89 x | -1.7 x |
EV / FCF | -2.24 x | -9.37 x | -6.55 x | -4.55 x | -4.59 x | -1.28 x | -1.49 x | -1.42 x |
FCF Yield | -44.6% | -10.7% | -15.3% | -22% | -21.8% | -78.2% | -67% | -70.4% |
Price to Book | 2.31 x | 4.05 x | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 48,958 | 56,204 | 61,258 | 61,475 | 62,029 | 62,633 | - | - |
Reference price 2 | 10.88 | 22.86 | 16.05 | 6.710 | 9.620 | 4.700 | 4.700 | 4.700 |
Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 3/15/23 | 3/7/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 64.19 | 104.9 | 77.45 | 151.9 | 58.75 | 65.73 | 108.5 | 112.3 |
EBITDA 1 | -166.3 | -119.4 | -191.5 | -109.6 | -158.6 | -194.8 | -101.9 | -173.2 |
EBIT 1 | -177.2 | -131.1 | -202.8 | -121.4 | -168.2 | -185.1 | -171.1 | -190.6 |
Operating Margin | -276.04% | -124.96% | -261.85% | -79.91% | -286.38% | -281.62% | -157.78% | -169.69% |
Earnings before Tax (EBT) 1 | -151.8 | -129.7 | -202.1 | -119.8 | -9.058 | -183.8 | -163.5 | -187.8 |
Net income 1 | -151.8 | -129.7 | -202.1 | -119.8 | -9.058 | -184.6 | -126.7 | -170.2 |
Net margin | -236.51% | -123.7% | -260.97% | -78.82% | -15.42% | -280.9% | -116.82% | -151.46% |
EPS 2 | -3.160 | -2.470 | -3.370 | -1.950 | -0.1500 | -2.989 | -1.822 | -2.052 |
Free Cash Flow 1 | -141.4 | -117.8 | -150 | -90.58 | -79.97 | -180.2 | -197.3 | -207.2 |
FCF margin | -220.35% | -112.32% | -193.72% | -59.62% | -136.12% | -274.18% | -181.85% | -184.47% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 3/15/23 | 3/7/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 14.15 | 11.1 | 26.01 | 41.73 | 73.1 | 24.5 | 13.14 | 10.4 | 10.72 | 9.104 | 17.25 | 14.18 | 21.4 | 12.5 | 12.5 |
EBITDA 1 | - | - | - | - | - | - | - | - | -47.45 | -51.91 | -49.57 | -47.81 | -46.15 | - | - |
EBIT 1 | -58.24 | -66.64 | -41.81 | -24.96 | 11.98 | -38.43 | -44.96 | -35.5 | -49.35 | -53.75 | -44.19 | -48.99 | -42.55 | -58.6 | -58.6 |
Operating Margin | -411.65% | -600.29% | -160.76% | -59.8% | 16.39% | -156.87% | -342.28% | -341.46% | -460.39% | -590.4% | -256.12% | -345.41% | -198.85% | -468.8% | -468.8% |
Earnings before Tax (EBT) 1 | -58.02 | -66.44 | -41.3 | -24.81 | 12.8 | -38.01 | 57.47 | 17.55 | -46.07 | -52.19 | -43.66 | -48.87 | -41.11 | -58.6 | -58.6 |
Net income 1 | -58.02 | -66.44 | -41.3 | -24.81 | 12.8 | -38.01 | 57.47 | 17.55 | -46.07 | -52.19 | -43.9 | -48.46 | -41.83 | -58.6 | -58.6 |
Net margin | -410.14% | -598.53% | -158.82% | -59.46% | 17.51% | -155.16% | 437.49% | 168.84% | -429.78% | -573.26% | -254.44% | -341.71% | -195.48% | -468.8% | -468.8% |
EPS 2 | -0.9500 | -1.080 | -0.6700 | -0.4000 | 0.2100 | -0.6100 | 0.9200 | 0.2800 | -0.7500 | -0.8400 | -0.7189 | -0.7751 | -0.6757 | -0.9000 | -0.9000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/24/22 | 5/3/22 | 8/8/22 | 11/3/22 | 3/15/23 | 5/9/23 | 8/9/23 | 11/6/23 | 3/7/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 216 | 181 | - | - | 230 | 64 | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | -141 | -118 | -150 | -90.6 | -80 | -180 | -197 | -207 |
ROE (net income / shareholders' equity) | -64.1% | -49.3% | -75.5% | -62.8% | -6.15% | -332% | - | -553% |
ROA (Net income/ Total Assets) | -47.1% | - | - | - | - | - | - | - |
Assets 1 | 322.3 | - | - | - | - | - | - | - |
Book Value Per Share | 4.710 | 5.640 | - | - | - | - | - | - |
Cash Flow per Share | - | -2.130 | - | - | - | - | - | - |
Capex 1 | 4.29 | 5.91 | 6.2 | 3.62 | 1.76 | 3.32 | 1.91 | 1.54 |
Capex / Sales | 6.68% | 5.63% | 8.01% | 2.38% | 3% | 5.06% | 1.76% | 1.37% |
Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 3/15/23 | 3/7/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.14% | 267M | |
+9.99% | 114B | |
+12.01% | 107B | |
-3.07% | 22.22B | |
-0.67% | 21.28B | |
-4.64% | 18.8B | |
-6.90% | 17.51B | |
-39.36% | 17.17B | |
+5.82% | 14.14B | |
+33.05% | 12.2B |
- Stock Market
- Equities
- MGNX Stock
- Financials MacroGenics, Inc.